

Reply to Letter to the Editor: "Critical Appraisal of Isorhamnetin as a Candidate for Pulmonary Arterial Hypertension Treatment"

To the Editor,

Thank you to the readers¹ for their attention to the article² and for providing constructive suggestions and in-depth interpretations. It is believed that the suggestions of "letter to the editors" further enriched the article with new content and perspectives. There is limited research on the biological effects of isorhamnetin on pulmonary artery hypertension, which encourages future experimental and clinical investigations. The novel drug delivery method and pharmacokinetic study of isorhamnetin proposed by the authors of the letter, along with its scientifically supported protective effects against endothelial damage, are highly innovative and promising. Heartfelt appreciation to the editors and reviewers for their dedicated efforts in facilitating the publication of this research.

REFERENCES

1. Iftikhar MK, Iftikhar Q. Critical appraisal of isorhamnetin as a candidate for pulmonary arterial hypertension treatment. *Anatol J Cardiol.* 2025;29(7):375.
2. Shao C, Xia W, Liu Y. Bioinformatic analysis and molecular docking identify isorhamnetin is a candidate compound in the treatment of pulmonary artery hypertension. *Anatol J Cardiol.* 2025;29(2):52-65. [CrossRef]

LETTER TO THE EDITOR REPLY

Yang Liu 

Department of Internal and Pediatrics,
School of Clinical Medicine, Qilu Medical
University, Zibo, Shandong, China

Corresponding author:

Yang Liu

✉ 13009726899@163.com

Cite this article as: Liu Y. Reply to letter to the editor: "Critical appraisal of isorhamnetin as a candidate for pulmonary arterial hypertension treatment." *Anatol J Cardiol.* 2025; 29(7):376.



Copyright©Author(s) - Available online at anatoljcardiol.com.
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

DOI:10.14744/AnatolJCardiol.2025.5304